Emory and other universities' licensing deals shouldn't perpetuate inequity
Emory University's termination-for-challenge clause in its molnupiravir deal with the Medicines Patent Pool does not "serve humanity."
Stay updated with breaking news from Technology Access Pool. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Emory University's termination-for-challenge clause in its molnupiravir deal with the Medicines Patent Pool does not "serve humanity."
The global stakes for vaccine access - IAVI. COVID-19 has made stark inequities in global access to vaccines, drugs, and diagnostics more visible and alarming
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
Despite multiple technological breakthroughs in the fight to control COVID-19, twice as many people died from the virus in 2021 compared with the previous year. The omicron variant is a stark reminder that effective vaccines are merely the first step toward ending the pandemic. Until we establish a process to manufacture vaccines at scale and distribute them where they are
By Mariana Mazzucato and Jayati GhoshLONDON — Despite multiple technological breakthroughs in the fight to control COVID-19, twice as many people died from it in 2021 compared to 2020. The Omicron variant is a stark reminder that effective vaccines are merely the first step towards ending the pandemic. Until we establish a process to manufacture vaccines at scale and